Bioventus Inc. (BVS) Tops Q3 EPS by 4c ; Offers Guidance

Bioventus Inc. (NASDAQ: BVS) reported Q3 EPS of $0.15, $0.04 better than the analyst estimate of $0.11. Revenue for the quarter came in at $138.7 million versus the consensus estimate of $137.65 million.

GUIDANCE:

Bioventus Inc. sees FY2025 EPS of $0.64-$0.68, versus the consensus of $0.64. Bioventus Inc. sees FY2025 revenue of $560-570 million, versus the consensus of $566.8 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• RH (RH) Tops Q1 EPS by 12c
• 22nd Century Group files prospectus for warrant share resale